ArticleJournal of inflammation research2026
Response to Febuxostat in Elderly Gout Patients with Clinical Subtypes of Hyperuricemia: A Prospective Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout.International journal of rheumatic diseases · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Previous clinical studies have suggested potential differences in the response of different subtypes to febuxostat treatment. However, research on elderly gout patients, particularly those with chronic kidney disease (CKD) stage 3, remains lacking. This study aims to compare febuxostat response across subtypes in elderly gout patients. Methods: A prospective cohort study was conducted to compare the efficacy and safety of febuxostat (20 or 40 mg daily) in 490 gout patients with the clinical subtypes for 12 weeks. Hyperuricemia was defined as the renal underexcretion subtype when UUE ≤ 600 mg/d/1.73m Results: Fewer participants with combined subtype achieved the SU target, 45.57% compared with 69.69% with renal overload subtype, 63.40% with renal underexcretion subtype and 64.06% with normal subtype. Participants with the normal subtype had the lowest baseline eGFR but showed the greatest improvement after treatment (an increase of 5.67 mL/min/1.73 m Conclusion: Elderly gout patients with the combined subtype exhibit poorer response to febuxostat compared to other subtypes. Urate-lowering therapy improved renal function, particularly in patients with normal subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.